Insights

Innovative Drug Platform Oncopeptides leverages proprietary Peptide Drug Conjugate (PDC) and SPiKE platforms to develop targeted cancer therapies, presenting opportunities for collaborations with pharmaceutical firms interested in novel drug delivery technologies.

Expanding Market Presence The company's recent regional expansion into Italy and partnerships across Europe, the Middle East, and Africa indicate a strategic focus on increasing market penetration, creating potential sales channels for distribution and regional support.

Clinical Development Momentum Initiation of studies like MARINA and the focus on real-world data at international conferences suggest ongoing clinical advancements, which could attract partners interested in early-stage or specialty oncology solutions.

Partnership Growth Recent collaborations with Iomedico and SD Pharma demonstrate a strong focus on strategic alliances, offering opportunities for joint ventures, licensing, or co-marketing agreements in oncology markets.

Financial Opportunity With revenue in the range of 1 to 10 million USD and focused on difficult-to-treat cancers, Oncopeptides presents a niche sales opportunity for companies targeting innovative biotech solutions in oncology, especially within European and emerging markets.

Similar companies to Oncopeptides AB

Oncopeptides AB Tech Stack

Oncopeptides AB uses 8 technology products and services including SAS, Tableau, RSS, and more. Explore Oncopeptides AB's tech stack below.

SAS
Business Intelligence
Tableau
Business Intelligence
RSS
Content Management System
Cybot
Cookie Compliance
Medidata
Health Platform
Plyr
Video Players
Nginx
Web Servers
Facebook
Widgets

Media & News

Oncopeptides AB's Email Address Formats

Oncopeptides AB uses at least 2 format(s):

Oncopeptides AB Email Formats	Example	Percentage
First.Last@oncopeptides.com	John.Doe@oncopeptides.com	91%
FirstLast@oncopeptides.com	JohnDoe@oncopeptides.com	4%
First.Middle.Last@oncopeptides.com	John.Michael.Doe@oncopeptides.com	3%
LastF@oncopeptides.com	DoeJ@oncopeptides.com	2%
First.Last@oncopeptides.se	John.Doe@oncopeptides.se	96%
First.Middle.Last@oncopeptides.se	John.Michael.Doe@oncopeptides.se	3%
First-Last@oncopeptides.se	John-Doe@oncopeptides.se	1%

Frequently Asked Questions

Where is Oncopeptides AB's headquarters located?

Oncopeptides AB's main headquarters is located at 46 Luntmakargatan Stockholm, Stockholm 111 37 Sweden. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is Oncopeptides AB's phone number?

You can contact Oncopeptides AB's main corporate office by phone at

+46-70-569-5****

. For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is Oncopeptides AB's official website and social media links?

Oncopeptides AB's official website is oncopeptides.com and has social profiles on LinkedIn.

What is Oncopeptides AB's NAICS code?

Oncopeptides AB's NAICS code is 3254 - Pharmaceutical and Medicine Manufacturing.

How many employees does Oncopeptides AB have currently?

As of April 2026, Oncopeptides AB has approximately 85 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Executive Officer: S. H.Chief Operating Officer: E. N.Chief Financial Officer: H. B.. Explore Oncopeptides AB's employee directory with LeadIQ.

What industry does Oncopeptides AB belong to?

Oncopeptides AB operates in the Pharmaceutical Manufacturing industry.

What technology does Oncopeptides AB use?

Oncopeptides AB's tech stack includes SASTableauRSSCybotMedidataPlyrNginxFacebook.

What is Oncopeptides AB's email format?

Oncopeptides AB's email format typically follows the pattern of First.Last@oncopeptides.com. Find more Oncopeptides AB email formats with LeadIQ.

When was Oncopeptides AB founded?

Oncopeptides AB was founded in 2000.

Oncopeptides AB

Q: What is Oncopeptides AB's official website and social media links?

Oncopeptides AB's official website is oncopeptides.com. Oncopeptides AB has social profiles on LinkedIn.

Q: How many employees does Oncopeptides AB have currently?

Oncopeptides AB has approximately 85 employees.

Q: What technology does Oncopeptides AB use?

Oncopeptides AB's tech stack includes EndNote, Qlik, Plyr, Windows Server, SAS.

Q: What is Oncopeptides AB's NAICS code?

Oncopeptides AB's NAICS code is 3254 (Pharmaceutical and Medicine Manufacturing).

Pharmaceutical ManufacturingStockholm, Sweden51-200 Employees

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers. 

The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug, Pepaxti, is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO. For more information, visit: www.oncopeptides.com